Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Patient preferences in genetic newborn screening for rare diseases: study protocol

S. Martin, E. Angolini, J. Audi, E. Bertini, LP. Bruno, J. Coulter, A. Ferlini, F. Fortunato, V. Frankova, N. Garnier, Å. Grauman, E. Gross, B. Hauber, M. Hansson, J. Kirschner, F. Knieling, G. Kyosovksa, S. Ottombrino, A. Novelli, R. Raming, S....

. 2024 ; 14 (4) : e081835. [pub] 20240419

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24014283

INTRODUCTION: Rare diseases (RDs) collectively impact over 30 million people in Europe. Most individual conditions have a low prevalence which has resulted in a lack of research and expertise in this field, especially regarding genetic newborn screening (gNBS). There is increasing recognition of the importance of incorporating patients' needs and general public perspectives into the shared decision-making process regarding gNBS. This study is part of the Innovative Medicine Initiative project Screen4Care which aims at shortening the diagnostic journey for RDs by accelerating diagnosis for patients living with RDs through gNBS and the use of digital technologies, such as artificial intelligence and machine learning. Our objective will be to assess expecting parent's perspectives, attitudes and preferences regarding gNBS for RDs in Italy and Germany. METHODS AND ANALYSIS: A mixed method approach will assess perspectives, attitudes and preferences of (1) expecting parents seeking genetic consultation and (2) 'healthy' expecting parents from the general population in two countries (Germany and Italy). Focus groups and interviews using the nominal group technique and ranking exercises will be performed (qualitative phase). The results will inform the treatment of attributes to be assessed via a survey and a discrete choice experiment (DCE). The total recruitment sample will be 2084 participants (approximatively 1000 participants in each country for the online survey). A combination of thematic qualitative and logit-based quantitative approaches will be used to analyse the results of the study. ETHICS AND DISSEMINATION: This study has been approved by the Erlangen University Ethics Committee (22-246_1-B), the Freiburg University Ethics Committee (23-1005 S1-AV) and clinical centres in Italy (University of FerraraCE: 357/2023/Oss/AOUFe and Hospedale Bambino Gesu: No.2997 of 2 November 2023, Prot. No. _902) and approved for data storage and handling at the Uppsala University (2022-05806-01). The dissemination of the results will be ensured via scientific journal publication (open access).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24014283
003      
CZ-PrNML
005      
20240905134228.0
007      
ta
008      
240725s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/bmjopen-2023-081835 $2 doi
035    __
$a (PubMed)38643010
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Martin, Sylvia $u Center for Research and Bioethics, Uppsala Universitet, Uppsala, Sweden sylvia.martin@crb.uu.se $1 https://orcid.org/0000000237067669
245    10
$a Patient preferences in genetic newborn screening for rare diseases: study protocol / $c S. Martin, E. Angolini, J. Audi, E. Bertini, LP. Bruno, J. Coulter, A. Ferlini, F. Fortunato, V. Frankova, N. Garnier, Å. Grauman, E. Gross, B. Hauber, M. Hansson, J. Kirschner, F. Knieling, G. Kyosovksa, S. Ottombrino, A. Novelli, R. Raming, S. Sansen, C. Saier, J. Veldwijk
520    9_
$a INTRODUCTION: Rare diseases (RDs) collectively impact over 30 million people in Europe. Most individual conditions have a low prevalence which has resulted in a lack of research and expertise in this field, especially regarding genetic newborn screening (gNBS). There is increasing recognition of the importance of incorporating patients' needs and general public perspectives into the shared decision-making process regarding gNBS. This study is part of the Innovative Medicine Initiative project Screen4Care which aims at shortening the diagnostic journey for RDs by accelerating diagnosis for patients living with RDs through gNBS and the use of digital technologies, such as artificial intelligence and machine learning. Our objective will be to assess expecting parent's perspectives, attitudes and preferences regarding gNBS for RDs in Italy and Germany. METHODS AND ANALYSIS: A mixed method approach will assess perspectives, attitudes and preferences of (1) expecting parents seeking genetic consultation and (2) 'healthy' expecting parents from the general population in two countries (Germany and Italy). Focus groups and interviews using the nominal group technique and ranking exercises will be performed (qualitative phase). The results will inform the treatment of attributes to be assessed via a survey and a discrete choice experiment (DCE). The total recruitment sample will be 2084 participants (approximatively 1000 participants in each country for the online survey). A combination of thematic qualitative and logit-based quantitative approaches will be used to analyse the results of the study. ETHICS AND DISSEMINATION: This study has been approved by the Erlangen University Ethics Committee (22-246_1-B), the Freiburg University Ethics Committee (23-1005 S1-AV) and clinical centres in Italy (University of FerraraCE: 357/2023/Oss/AOUFe and Hospedale Bambino Gesu: No.2997 of 2 November 2023, Prot. No. _902) and approved for data storage and handling at the Uppsala University (2022-05806-01). The dissemination of the results will be ensured via scientific journal publication (open access).
650    _2
$a novorozenec $7 D007231
650    _2
$a lidé $7 D006801
650    12
$a novorozenecký screening $7 D015997
650    12
$a pacientova volba $7 D057240
650    _2
$a umělá inteligence $7 D001185
650    _2
$a vzácné nemoci $x diagnóza $x genetika $7 D035583
650    _2
$a zjišťování skupinových postojů $7 D017144
655    _2
$a časopisecké články $7 D016428
700    1_
$a Angolini, Emanuele $u Research Unit of Neuromuscular and Neurodegenerative Disease, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Lazio, Italy
700    1_
$a Audi, Jennifer $u Takeda Pharmaceuticals International AG, Opfikon, Zürich, Switzerland
700    1_
$a Bertini, Enrico $u Research Unit of Neuromuscular and Neurodegenerative Disease, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Lazio, Italy
700    1_
$a Bruno, Lucia Pia $u Medical Genetics, University of Siena, Siena, Italy $u Telethon Institute of Genetics and Medicine, Napoli, Campania, Italy
700    1_
$a Coulter, Joshua $u Pfizer Inc, New York, New York, USA
700    1_
$a Ferlini, Alessandra $u Medical Genetics Unit, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
700    1_
$a Fortunato, Fernanda $u Medical Genetics Unit, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
700    1_
$a Frankova, Vera $u Institute for Medical Humanities, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Garnier, Nicolas $u Pfizer Inc, New York, New York, USA
700    1_
$a Grauman, Åsa $u Center for Research and Bioethics, Uppsala Universitet, Uppsala, Sweden
700    1_
$a Gross, Edith $u EURORDIS, Paris, Ile-de-France, France
700    1_
$a Hauber, Brett $u Pfizer Inc, New York, New York, USA
700    1_
$a Hansson, Mats $u Center for Research and Bioethics, Uppsala Universitet, Uppsala, Sweden
700    1_
$a Kirschner, Janbernd $u Department of Neuropediatrics and Muscle Disorders, Medical Center, University of Freiburg, Faculty of Medicine, Freiburg, Germany $1 https://orcid.org/0000000316187386
700    1_
$a Knieling, Ferdinand $u Erlangen University Hospital, Erlangen, Bayern, Germany
700    1_
$a Kyosovksa, Gergana $u Bulgarian Association for Personalised Medicine, Sofia, Bulgaria
700    1_
$a Ottombrino, Silvia $u Research Unit of Neuromuscular and Neurodegenerative Disease, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Lazio, Italy
700    1_
$a Novelli, Antonio $u Research Unit of Neuromuscular and Neurodegenerative Disease, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Lazio, Italy
700    1_
$a Raming, Roman $u Erlangen University Hospital, Erlangen, Bayern, Germany
700    1_
$a Sansen, Stefaan $u Sanofi-Aventis SA, Diegem, Belgium
700    1_
$a Saier, Christina $u Department of Neuropediatrics and Muscle Disorders, Faculty of Medicine, Freiburg, Germany
700    1_
$a Veldwijk, Jorien $u Erasmus Universiteit Rotterdam, Rotterdam, Netherlands
773    0_
$w MED00184484 $t BMJ open $x 2044-6055 $g Roč. 14, č. 4 (2024), s. e081835
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38643010 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134221 $b ABA008
999    __
$a ok $b bmc $g 2143839 $s 1226149
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 14 $c 4 $d e081835 $e 20240419 $i 2044-6055 $m BMJ open $n BMJ Open $x MED00184484
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Možnosti archivace